Axsome Therapeutics Inc
AXSMHealthcare|Biotechnology|USA
$233.80
-15.15 (-6.09%)
Tangible Book
$0.07
About
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Stock Price
+111.1%(1Y)
Pipeline Summary
38 total trials1
Phase 1
9
Phase 2
24
Phase 3
4
Phase 4
Completed: 22Recruiting: 8Terminated: 3Unknown: 3ENROLLING_BY_INVITATION: 2
Active Trials (8)
SUNOSI® (Solriamfetol) Pregnancy Registry
NCT06413420Narcolepsy
Recruiting
Enrollment: 1,731 participants
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
NCT07398417Fibromyalgia
Phase 3Recruiting
Enrollment: 620 participants
Dextromethorphan-Bupropion on Striatal Activity in Adults With Major Depressive Disorder
NCT07523048Major Depressive Disorder (MDD)
Phase 2Recruiting
Enrollment: 30 participants
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
NCT07484217Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Phase 3Recruiting
Enrollment: 508 participants
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
NCT06170970Multiple Sclerosis
Phase 2Recruiting
Enrollment: 46 participants
BioScore
6.5/10
Buy
Ownership
Recent Insider Trades
TABUTEAU HERRIOTSELL
2026-07-0149,666 shares @ $240.25
JEFFS ROGERSELL
2026-06-11572 shares @ $247.65
Coleman MarkSELL
2026-06-10643 shares @ $249
Mahony SusanSELL
2026-06-10600 shares @ $241.7
TABUTEAU HERRIOTSELL
2026-06-0949,670 shares @ $241.01
Recent News
2026-07-08 14:50:57
2026-07-07 16:35:42
2026-06-26 11:26:49
2026-06-17 14:36:13
Data last updated: Jul 12, 2026, 07:32 PM